Explore the SHIKARI®
Assay Portfolio

Adalimumab

• ADA-FD-HUMDrug level
• ADA-SPEC-ADADrug-specific level
• ADA-QNS-HUMADA · quantitative
• ADA-QLS-HUMADA · qualitative
• ADA-QNFT-HUMADA · free / total
• ADA-TCAP-NAb-HUMNAb

Explore six verified SHIKARI® assays for drug levels, anti-drug antibodies, free/total antibodies and neutralising antibodies.

Certolizumab

• CER-FD-CIMDrug level
• CER-QNS-CIMADA · quantitative
• CER-TCAP-NAb-CIMNAb

Explore three verified SHIKARI® assays for drug levels, quantitative anti-drug antibodies and neutralising antibodies.

Etanercept

• ETA-FD-ENBDrug level
• ETA-QLS-ENBADA · qualitative

Explore two verified SHIKARI® assays for quantitative etanercept concentration and qualitative anti-etanercept antibodies.

Golimumab

• GOL-FD-SIMDrug level
• GOL-QNS-SIMADA · quantitative
• GOL-QLS-SIMADA · qualitative

Explore three verified SHIKARI® assays for drug levels and quantitative or qualitative anti-drug antibodies.

Infliximab

• Remicade® / general
• INF-FD-REMIDrug level
• INF-SPEC-INFDrug-specific level
• INF-QNS-REMIADA · quantitative
• INF-QLS-REMIADA · qualitative
• INF-QNFT-REMIADA · free / total
• INF-TCAP-NAb-REMINAb
• Remsima® (CT-P13)
• INF-FD-REMSDrug level
• INF-QNS-REMSADA · quantitative
• INF-QLS-REMSADA · qualitative
• INF-QNFT-REMSADA · free / total

Ten verified assays are separated into Remicade®/general and Remsima®-optimised families.

Benralizumab

• BEN-FD-FASDrug level
• BEN-QLS-FASADA · qualitative

Explore two verified SHIKARI® assays for quantitative benralizumab concentration and qualitative anti-benralizumab antibodies.

Canakinumab

• CAN-FD-ILADrug level
• CAN-QNS-ILAADA · quantitative
• CAN-QLS-ILAADA · qualitative

Explore three verified SHIKARI® assays for quantitative free canakinumab and qualitative or quantitative anti-canakinumab antibodies.

• DUP-FD-DUPDrug level
• DUP-QNS-DUPADA · quantitative
• DUP-QLS-DUPADA · qualitative

Explore three verified SHIKARI® assays for quantitative free dupilumab and qualitative or quantitative anti-dupilumab antibodies.

Guselkumab

• GUS-FD-TREDrug level
• GUS-SPEC-GUSDrug-specific level
• GUS-QNS-TREADA · quantitative

Explore three verified SHIKARI® assays: two quantitative guselkumab formats—including the specific mAb-based QS-GUS—and quantitative anti-guselkumab antibodies.

Ixekizumab

• IXE-FD-TALDrug level
• IXE-QLS-TALADA · qualitative

Explore two verified SHIKARI® assays for quantitative ixekizumab concentration and qualitative anti-ixekizumab antibodies.

Mepolizumab

• MEP-FD-NUCDrug level
• MEP-QLS-NUCADA · qualitative

Explore two verified SHIKARI® assays for quantitative mepolizumab concentration and qualitative anti-mepolizumab antibodies.

Mirikizumab

• MIR-FD-OMVDrug level
• MIR-QLS-OMVADA · qualitative

Explore two verified SHIKARI® assays for quantitative mirikizumab concentration and qualitative anti-mirikizumab antibodies.

Risankizumab

• RIS-FD-SKYDrug level
• RIS-SPEC-RISDrug-specific level Coming Soon
• RIS-QNS-SKYADA · quantitative
• RIS-QLS-SKYADA · qualitative

Explore three available SHIKARI® assays for free risankizumab and anti-risankizumab antibodies, with the specific quantitative QS-RIS assay coming soon.

Secukinumab

• SEC-FD-VERDrug level
• SEC-QLS-VERADA · qualitative

Explore two verified SHIKARI® assays for quantitative secukinumab concentration and qualitative anti-secukinumab antibodies.

Tocilizumab

• TOC-FD-ACTDrug level
• TOC-QNS-ACTADA · quantitative
• TOC-QLS-ACTADA · qualitative

Explore three SHIKARI® assays for tocilizumab concentration and anti-tocilizumab antibodies.

Ustekinumab

• UST-FD-STEDrug level
• UST-SPEC-USTDrug-specific level
• UST-QNS-STEADA · quantitative
• UST-QLS-STEADA · qualitative
• UST-TCAP-NAb-STENAb

Explore five verified SHIKARI® assays for drug concentration, specific free drug, binding antibodies and neutralising antibodies.

Atezolizumab

• ATE-FD-TECDrug level
• ATE-QLS-TECADA · qualitative

Explore two verified SHIKARI® assays for quantitative free atezolizumab and qualitative anti-atezolizumab antibodies.

Avelumab

• AVE-FD-BAVDrug level
• AVE-QLS-BAVADA · qualitative

Explore two verified SHIKARI® assays for quantitative free avelumab and qualitative anti-avelumab antibodies.

Durvalumab

• DUR-FD-IMFDrug level
• DUR-QLS-IMFADA · qualitative

Explore two verified SHIKARI® assays for quantitative free durvalumab and qualitative anti-durvalumab antibodies.

Ipilimumab

• IPI-FD-YERDrug level
• IPI-QNS-YERADA · quantitative
• IPI-QLS-YERADA · qualitative

Explore three verified SHIKARI® assays for quantitative free ipilimumab and qualitative or quantitative anti-ipilimumab antibodies.

Nivolumab

• NIV-FD-OPDDrug level
• NIV-SPEC-NIVDrug-specific level
• NIV-QNS-OPDADA · quantitative
• NIV-QLS-OPDADA · qualitative
• NIV-TCAP-NAb-OPDNAb

Explore five verified SHIKARI® assays for nivolumab concentration, specific drug level, anti-nivolumab antibodies and neutralising antibodies. The detail page covers all five products.

Pembrolizumab

• PEM-FD-KEYDrug level
• PEM-QNS-KEYADA · quantitative
• PEM-QLS-KEYADA · qualitative
• PEM-TCAP-NAb-KEYNAb

Explore four SHIKARI® assays for pembrolizumab concentration, anti-pembrolizumab antibodies and neutralising antibodies.

Aflibercept

• AFL-FD-EYLDrug level
• AFL-QNS-EYLADA · quantitative
• AFL-QLS-EYLADA · qualitative

Explore three verified SHIKARI® assays for free aflibercept and anti-aflibercept antibody research. The detail page covers all three products.

Bevacizumab

• BEV-FD-AADrug level
• BEV-QNS-AAADA · quantitative
• BEV-QLS-AAADA · qualitative
• BEV-TCAP-NAb-AANAb

Explore four verified SHIKARI® assays for free bevacizumab, quantitative and qualitative anti-bevacizumab antibodies, and neutralising antibodies. The detail page covers all four products.

Ramucirumab

• RAM-FD-CYRDrug level
• RAM-QLS-CYRADA · qualitative

Explore two verified SHIKARI® assays for free ramucirumab and anti-ramucirumab antibody research. The detail page covers all two products.

Ranibizumab

• RAN-FD-LUCDrug level

Explore the verified SHIKARI® assay for quantitative free-ranibizumab research. The detail page covers the current portfolio product.

Cetuximab

• CET-FD-ERBDrug level
• CET-QNS-ERBADA · quantitative
• CET-QLS-ERBADA · qualitative

Explore three verified SHIKARI® assays for free cetuximab and quantitative or qualitative anti-cetuximab antibodies. The detail page covers all three products.

Pertuzumab

• PER-FD-PERDrug level
• PER-SPEC-PERDrug-specific level
• PER-QLS-PERADA · qualitative

Explore three verified SHIKARI® assays for ligand-binding or drug-specific free pertuzumab and qualitative anti-pertuzumab antibodies. The detail page covers all three products.

Trastuzumab

• TRA-FD-HHDrug level
• TRA-SPEC-TRADrug-specific level
• TRA-QNS-HHADA · quantitative
• TRA-QLS-HHADA · qualitative
• TRA-TCAP-NAb-HHNAb

Explore five verified SHIKARI® assays for two free-trastuzumab formats, quantitative and qualitative anti-trastuzumab antibodies, and neutralising antibodies. The detail page covers all five products.

Abatacept

• ABA-FD-OREDrug level
• ABA-QNS-OREADA · quantitative
• ABA-QLS-OREADA · qualitative

Explore three verified SHIKARI® Abatacept assays for free-drug, quantitative anti-drug antibody and qualitative anti-drug antibody research. The detail page covers all three products.

Daratumumab

• DAR-FD-DARDrug level
• DAR-QLS-DARADA · qualitative

Explore two verified SHIKARI® assays for free-daratumumab and qualitative anti-daratumumab antibody research. The detail page covers both products.

Ocrelizumab

• OCR-FD-OCRDrug level
• OCR-QNS-OCRADA · quantitative

Explore two verified SHIKARI® assays for quantitative free-ocrelizumab and anti-ocrelizumab antibody research. The detail page covers both products.

Rituximab

• RIT-FD-RMDrug level
• RIT-QNS-RMADA · quantitative
• RIT-QLS-RMADA · qualitative
• RIT-TCAP-NAb-RMNAb

Explore four verified SHIKARI® assays for free-rituximab, quantitative and qualitative anti-rituximab antibodies, and neutralising antibodies. The detail page covers all four products.

Eculizumab

• ECU-SPEC-ECUDrug-specific level
• ECU-QNS-SOLADA · quantitative
• ECU-QLS-SOLADA · qualitative
• ECU-TCAP-NAb-SOLNAb

Explore four verified SHIKARI® assays for free-eculizumab, quantitative and qualitative anti-eculizumab antibodies, and neutralising antibodies. The detail page covers all four products.

Ravulizumab

• RAV-FD-ULTDrug level
• RAV-QNS-ULTADA · quantitative

Explore two verified SHIKARI® assays for quantitative free-ravulizumab and anti-ravulizumab antibody research. The detail page covers both products.

Natalizumab

• NAT-FD-TYSDrug level
• NAT-QNS-TYSADA · quantitative
• NAT-QLS-TYSADA · qualitative

Explore three verified SHIKARI® assays for free-natalizumab and anti-natalizumab antibody research. The detail page covers all three products.

Vedolizumab

• VED-FD-ENTDrug level
• VED-SPEC-VEDDrug-specific level
• VED-QNS-ENTADA · quantitative
• VED-QLS-ENTADA · qualitative
• VED-TCAP-NAb-ENTNAb

Explore five verified SHIKARI® assays spanning free drug, ADA and neutralising-antibody research. The detail page covers all five products.

Denosumab

• DEN-FD-PRODrug level
• DEN-QNS-PROADA · quantitative
• DEN-QLS-PROADA · qualitative

Explore three verified SHIKARI® assays for free-denosumab and quantitative or qualitative anti-denosumab antibody research. The detail page covers all three products.

Enfortumab

• ENF-FD-PADDrug level
• ENF-QLS-PADADA · qualitative

Explore two verified SHIKARI® assays for free-enfortumab and qualitative anti-enfortumab antibody research. The detail page covers both products.

Evolocumab

• EVO-FD-REPDrug level
• EVO-QLS-REPADA · qualitative

Explore two verified SHIKARI® Evolocumab assays for free-drug and qualitative anti-drug antibody research. The detail page covers both products.

Filgrastim

• FIL-QNS-FRAADA · quantitative

Explore one verified SHIKARI® Filgrastim assay for quantitative anti-drug antibody research. The detail page covers this product.

Omalizumab

• OMA-FD-XOLDrug level
• OMA-QNS-XOLADA · quantitative
• OMA-QLS-XOLADA · qualitative

Explore three verified SHIKARI® assays for quantitative free omalizumab and qualitative or quantitative anti-omalizumab antibodies.

Palivizumab

• PAL-FD-SYNDrug level
• PAL-QNS-SYNADA · quantitative
• PAL-QLS-SYNADA · qualitative

Explore three verified SHIKARI® Palivizumab assays for free-drug, quantitative anti-drug antibody and qualitative anti-drug antibody research. The detail page covers all three products.

Semaglutide

• SEM-QNS-OZEADA · quantitative

Explore one verified SHIKARI® Semaglutide assay for quantitative anti-drug antibody research. The detail page covers this product.